Company
Headquarters: Tianjin, China
Employees: 2,943
CN¥4.52 Billion
CNY as of Jan. 1, 2026
US$644.4 Million
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Tianjin Tianyao Pharmaceuticals Co., Ltd. engages in the research, manufacture, and export of pharmaceutical APIs in Asia. It primarily provides corticosteroid, cardio cerebrovascular, and analgesic APIs and formulations. The company offers bulk drugs, including dexamethasone, dexamethasone sodium phosphate, dexamethasone acetate, triamcinlone acetonide acetate, prednisone acetate, prednisone, prednisolone, flucinonide, halcinonide, triamcinolone acetonide, clobetasol propionate, betamethasone, methylprednisolone hydrocortisone acetate, methylprednisolone, and triamcinolone. The company is based in Tianjin, China. Tianjin Tianyao Pharmaceuticals Co., Ltd. (SHSE : 600488) operates as a subsidiary of Jinhushen Biomedical Technology Co., Ltd.
Tianjin Tianyao Pharmaceuticals Co. Ltd has the following listings and related stock indices.
Stock: SSE: 600488